Richard Dilon

30PUBLICATIONS
205CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Transplantation immunologyMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jul 03, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard

|May 28, 2024
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.

Luísa Corrêa de Araújo Koury, Haesook T Kim, Maria Soledad Undurraga

|Mar 01, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).

Ing Soo Tiong, Devendra K Hiwase, Emad Abro

|Feb 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Jad Othman, Nicola Potter, Adam Ivey

|Jan 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.

Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman

Pageof 5

Frequent Collaborators

10 joint publications

Jad Othman

9 joint publications

Sylvie Freeman

5 joint publications

Andrew Wei

5 joint publications

Ing Soo Tiong